๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Omeros Corporation (OMER)
NASDAQ: OMER ยท Real-Time Price ยท USD
13.21
-0.80 (-5.71%)
At close: Nov 20, 2026, 4:00 PM EST
13.34
+0.13 (0.98%)
After-hours: Nov 20, 2026, 7:52 PM EST

Omeros Earnings Call Transcripts

Fiscal Year 2026

  • YARTEMLEA sales grew strongly in Q3 as adoption and outpatient use broadened, alongside a second quarter of positive operating cash flow. Adjusted net income improved, while GAAP results were weighed down by volatile non-cash note remeasurements.

  • YARTEMLEA achieved $32.2M in gross sales and $13.2M net income in its first full quarter, with strong adoption and positive cash flow. Capital structure was strengthened through share and note repurchases, and CMS granted favorable reimbursement. The company expects continued growth and aims for cash flow positivity by mid-2027.

  • AGM 2026

    The meeting approved all proposals, including director elections and compensation plans, and highlighted a transformative year with the YARTEMLEA launch, strengthened financials, and pipeline progress. Management addressed shareholder questions on product adoption, competition, and capital strategy.

  • YARTEMLEA's U.S. launch drove $9.9M in Q1 net revenue with rapid adoption and strong payer support. Novo Nordisk deal secured $240M upfront, and the company ended Q1 with $135.3M in cash. CMS J-code and NTAP are expected to further boost access and reimbursement.

  • FDA Announcement

    YARTEMLEA received FDA approval as the first therapy for TA-TMA, showing strong efficacy and a favorable safety profile. The launch is expected to shift treatment paradigms, with broad label coverage, robust reimbursement support, and a focus on early intervention and outpatient use.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022